New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Merck & Co., Inc.

MRK

Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.

Revenue
+4.68%
EPS
−12.1%
Free cash flow
−19.3%
Total debt
+24.3%

Quarter to September 2026, against a year earlier

134.96 2.22 +1.67%
Market cap
$328.6B
P/E
137×
Fwd P/E FY26e
105×
Dividend yield
2.56%
F-score
4/9
ROIC
4.56%
Net debt / EBITDA
1.2×
Payout ratio
3.5×

Merck & Co., Inc. (MRK) EPS (diluted)

Alert me on EPS (diluted)

Merck & Co., Inc.'s EPS (diluted) for fiscal 2025 was $7.28, up 8.01% from $6.74 in fiscal 2024. Over the twelve months to Sep 30, 2026 it was $0.97. Over the past ten years it has ranged from $0.14 (fiscal 2023) to $7.28 (fiscal 2025) — the current reading is the highest in ten years. Merck & Co., Inc. ranks 12th of 20 Drug Manufacturers General companies by EPS (diluted).

EPS (diluted), annual

Embed this chart

Annual newest first

Period EPS (diluted) Change
FY2025 $7.28 8.01%
FY2024 $6.74 4,714.29%
FY2023 $0.14 (97.55%)
FY2022 $5.71 11.09%
FY2021 $5.14 84.89%
FY2020 $2.78 (27.03%)
FY2019 $3.81 64.22%
FY2018 $2.32 149.46%
FY2017 $0.93 (34.23%)
FY2016 $1.41 (9.35%)

Quarterly newest first

Period EPS (diluted) Change
Sep 2026 $2.04 —
Jun 2026 −$0.54 —
Mar 2026 −$1.72 —
Dec 2025 $1.19 (48.71%)
43 more quarters

Against its own ten years

Low $0.14 High $7.28
Ten-year median $2.78
Current reading's percentile 100

EPS (diluted) against peers

What EPS (diluted) is

Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.

Reported line item

The full definition of EPS (diluted) →

More on MRK